CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Advagene Biopharma Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Advagene Biopharma Co Ltd
6F, No.308, Section 1
Neihu Road, Neihu District
Phone: +886 227970073p:+886 227970073 TAIPEI, 114  Taiwan Ticker: 67096709
Business Summary
Advagene Biopharma Co., Ltd. is a Taiwan-based company mainly enagegd in the research and development of new drug products through its detoxified LT adjuvant technology platform. The products developed by the Company include nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy) and other vaccines. The detoxified LT adjuvant is genetically engineered to detoxify the heat-labile LT protein (or Escherichia coli heat-labile enterotoxin protein) produced by Escherichia coli.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board BryonChen 6/20/2019 3/17/2014
Acting General Manager, Director Yu-ShenHsu 6/20/2019 4/1/2014
Head of Accounting RongdunSu 3/11/2022 1/10/2018
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 53,380,000 (As of 8/9/2024)
Shareholders: 2,153
Stock Exchange: TPO
Fax Number: +886 227970083


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024